Skip to Main Content

STAT biotech reporter Damian Garde reviewed federal filings from all 162 companies on the Nasdaq Biotech Index to see how they compensated their executives during last year’s Wall Street slump.

He found some surprises.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!